Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pharmacotherapy Considerations in Ckd Patients With Covid-19, a Narrative Review Pubmed



Dashtikhavidaki S1 ; Khalili H1 ; Nourian A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Kidney Diseases Published:2020


Abstract

Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensin-aldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19. © 2020, Iranian Society of Nephrology. All rights reserved.
Related Docs
View other Related Docs
1. Cardiovascular Complications of Covid-19: Pharmacotherapy Perspective, Cardiovascular Drugs and Therapy (2021)
2. Pathogenesis, Clinical Manifestations and Complications of Coronavirus Disease 2019 (Covid-19), Future Microbiology (2020)
3. Considerations for Statin Therapy in Patients With Covid-19, Pharmacotherapy (2020)
4. Covid-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods, Anti-Cancer Agents in Medicinal Chemistry (2021)
5. Pharmacotherapeutic Considerations in Solid Organ Transplant Patients With Covid-19, Expert Opinion on Pharmacotherapy (2020)
6. Covid-19’S Immuno-Pathology and Cardiovascular Diseases, Journal of Investigative Medicine (2023)
7. Prevalence, Risk Factors and Outcomes Associated With Acute Kidney Injury in Patients Hospitalized for Covid-19: A Comparative Study Between Diabetic and Nondiabetic Patients, Journal of Diabetes Research (2021)
8. Coagulopathy: Another Side Effect of Coronavirus Infection, Journal of Cardiovascular and Thoracic Research (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (4)
Hossein Khalili (3)
Other Related Docs
9. Molecular Signaling Pathways, Pathophysiological Features in Various Organs, and Treatment Strategies in Sars-Cov2 Infection, Acta Histochemica (2022)
10. Clinical and Radiologic Characteristics of Covid-19 in Patients With Ckd, Iranian Journal of Kidney Diseases (2020)
11. Case Fatality Rate of Covid-19: A Systematic Review and Meta-Analysis, Journal of Preventive Medicine and Hygiene (2021)
12. Association Between Cardiometabolic Risk Factors and Covid-19 Susceptibility, Severity and Mortality: A Review, Journal of Diabetes and Metabolic Disorders (2021)
13. How to Overcome Cardiovascular Challenges in Covid-19 Patients: A Guide for Common Practice, Acta Biomedica (2020)
14. A Narrative Review on Adverse Drug Reactions of Covid-19 Treatments on the Kidney, Open Medicine (Poland) (2024)
15. Covid-19 and Cardiovascular Diseases, Advances in Experimental Medicine and Biology (2021)
16. Management of Patients With Liver Transplant and Chronic Liver Diseases During Covid-19 Pandemic: A Brief Review, Archives of Iranian Medicine (2020)
17. Different Incidences of Acute Kidney Injury (Aki) and Outcomes in Covid-19 Patients With and Without Non-Azithromycin Antibiotics: A Retrospective Study, Journal of Medical Virology (2021)
18. Covid-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms, Journal of Molecular Histology (2020)
19. Well-Controlled Vs Poorly-Controlled Diabetes in Patients With Covid-19: Are There Any Differences in Outcomes and Imaging Findings?, Diabetes Research and Clinical Practice (2020)
20. Cardiovascular Disease in Covid-19: A Systematic Review and Meta-Analysis of 10,898 Patients and Proposal of a Triage Risk Stratification Tool, Egyptian Heart Journal (2020)
21. The Prevalence of Electrolyte Imbalances and Their Relationship With Disease Severity in Hospitalized Covid-19 Patients, Archives of Clinical Infectious Diseases (2022)
22. Immunology, Immunopathogenesis and Immunotherapeutics of Covid-19; an Overview, International Immunopharmacology (2021)
23. The Risk Factors and Clinical Outcomes Associated With Acute Kidney Injury in Patients With Covid-19: Data From a Large Cohort in Iran, Kidney and Blood Pressure Research (2021)
24. Identifying Data Elements and Key Features of a Mobile-Based Self-Care Application for Patients With Covid-19 in Iran, Health Informatics Journal (2021)
25. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (Covid-19), Journal of Cardiovascular Pharmacology (2020)
26. Comparing the Sensitivity and Specificity of Lung Ct-Scan With Rt-Pcr for Diagnosis of Covid-19, Current Medical Imaging (2023)
27. Chest Computed Tomography Manifestation of Coronavirus Disease 2019 (Covid-19) in Patients With Cardiothoracic Conditions, Journal of Thoracic Imaging (2020)
28. The Prognostic Value of Comorbidity for the Severity of Covid-19: A Systematic Review and Meta-Analysis Study, PLoS ONE (2021)
29. Covid-19: Why Does Disease Severity Vary Among Individuals?, Respiratory Medicine (2021)
30. Clinical and Laboratory Characteristics of Patients With Hypertension Admitted to Baharloo Hospital in Tehran With a Diagnosis of Covid-19 and Its Association With Mortality in 2020, Journal of Knowledge and Health in Basic Medical Sciences (2021)
31. A Review of Pathophysiology, Mortality, Risk Factors and Protective Measures of Acute Kidney Injury in Covid-19 Patients With Underlying Kidney Disease and Kidney Transplant Recipients, Journal of Nephropathology (2022)
32. Clinical Symptoms and Types of Samples Are Critical Factors for the Molecular Diagnosis of Symptomatic Covid-19 Patients: A Systematic Literature Review, International Journal of Microbiology (2021)
33. Efficacy and Safety of Corticosteroids in Covid-19 Based on Evidence for Covid-19, Other Coronavirus Infections, Influenza, Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis; [Efficacite Et Innocuite Des Corticosteroides Dans Le Traitement De La Covid-19 Selon Des Donnees Pour La Covid-19, D’Autres Infections Aux Coronavirus, L’Influenza, La Pneumonie Extrahospitaliere Et Le Syndrome De Detresse Respiratoire Aigue: Revue Systematique Et Meta-Analyse], CMAJ (2020)
34. Cardiovascular Implications of the Covid-19: Management of Complications and Drug Safety Concerns, Journal of Research in Medical Sciences (2022)
35. Immunopathological Similarities Between Covid-19 and Influenza: Investigating the Consequences of Co-Infection, Microbial Pathogenesis (2021)
36. Biochemical Parameters and Pathogenesis of Sars-Cov-2 Infection in Vital Organs: Covid-19 Outbreak in Iran, New Microbes and New Infections (2020)
37. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
38. Red Flags of Poor Prognosis in Pediatric Cases of Covid-19: The First 6610 Hospitalized Children in Iran, BMC Pediatrics (2021)
39. Covid-19 Infection and Stroke Risk, Reviews in the Neurosciences (2021)
40. Introduction on Coronavirus Disease (Covid-19) Pandemic: The Global Challenge, Advances in Experimental Medicine and Biology (2021)
41. Severe Acute Kidney Injury and Chronic Kidney Disease Are Paramount Risk Factors for Mortality in Hospitalized Cases With Covid-19, Journal of Mazandaran University of Medical Sciences (2023)
42. Long-Term Major Adverse Cardiovascular Events in Patients With Moderate and Severe Covid-19: A Focus on Early Statin Use and Previous Cvd, Journal of Tehran University Heart Center (2023)
43. Renal, Cardiac, Neurological, Cutaneous and Coagulopathic Long-Term Manifestations of Covid-19 After Recovery; a Review, Epidemiology and Infection (2022)
44. Cardiovascular Manifestations in Covid-19 Patients: A Systematic Review and Meta-Analysis, Journal of Cardiovascular and Thoracic Research (2021)
45. Death Due to Covid-19 in a Patient With Diabetes, Epilepsy, and Gout Comorbidities, Clinical Case Reports (2020)
46. A Prospective Study on Risk Factors for Acute Kidney Injury and All-Cause Mortality in Hospitalized Covid-19 Patients From Tehran (Iran), Frontiers in Immunology (2022)
47. The Association Between Cardiac Injury and Outcomes in Hospitalized Patients With Covid-19, Internal and Emergency Medicine (2020)
48. Covid-19: Review of a 21St Century Pandemic From Etiology to Neuro-Psychiatric Implications, Journal of Alzheimer's Disease (2020)
49. Covid-19 and Varicocele: The Possible Overlap Factors and the Common Therapeutic Approaches, American Journal of Reproductive Immunology (2022)
50. Current Treatments and Therapeutic Options for Covid-19 Patients: A Systematic Review, Infectious Disorders - Drug Targets (2022)